Phase I/II Study in WT1-Expressing Non-small Cell Lung Cancer and Mesothelioma, Comparing Cellular Adoptive Immunotherapy With Polyclonal Autologous Central Memory to Naïve CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T-Cell Receptor
Phase of Trial: Phase I/II
Latest Information Update: 02 May 2017
At a glance
- Drugs JTCR 016 (Primary)
- Indications Mesothelioma; Non-small cell lung cancer
- Focus Adverse reactions; Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 26 Apr 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
- 01 Nov 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.